AR and prostate carcinoma: Therefore, in response to androgen/AR-targeted therapy in hypoxia, prostate cancer cells most capable of redirecting glucose flux from PPP to glycolysis may maintain glucose metabolism and utilization, thereby gaining survival and growth advantage and evading therapy.